European Journal of Haematology

Article	Citations
Plasma microbial cell‐free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia	115
Issue Information	65
	43
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity‐induced rash in patients with multiple myeloma	41
Pixantrone as a bridge to CAR‐T treatment in high‐grade transformation of follicular lymphoma	40
Application of thromboelastography to predict the severity of bleeding after chimeric antigen receptor (CAR)‐T cell therapy in patients with hematological malignancy	33
The association of age and adverse events of PEG‐asparaginase in a pediatric tertiary care hospital; a retrospective review	30
Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect	29
	29
Letter to the Editor: Fine‐needle aspiration cytology and core‐needle biopsy in the diagnosis of lymphadenopathies: Words of endorsement	28
Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial	23
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes	23
Myeloproliferative Neoplasms and Dementia Risk: A Population‐Based Cohort Study	23
Issue Information	22
Issue Information	22
Effects of tertiary palliative care on the pattern of end‐of‐life care in patients with hematologic malignancies in Korea	21
Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk underg	20
Augmenter of liver regeneration promotes drug resistance of acute lymphoblastic leukemia through the alteration of mitochondrial functions and the inhibition of the mitochondrial apoptosis pathway	20
Flow cytometry for comprehensive assessment of platelet functional activity in response to ADP stimulation	19
Comparison of Hetrombopag and Eltrombopag Added to First‐Line Immunosuppressive Therapy in Severe Aplastic Anemia	19
Enhancing thalassemia gene carrier identification in non‐anemic populations using artificial intelligence erythrocyte morphology analysis and machine learning	18
Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes	18
Impact of Gut Microbiota and Inflammatory Cytokines on Immune Thrombocytopenia	17
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study	17
Post‐transplant maintenance therapy in patients with FLT3‐mutated acute myeloid leukemia: Real‐world treatment patterns and outcomes	17

Utilization and outcome disparities in allogeneic hematopoietic stem cell transplant in the United States	17
Long‐term effectiveness of eculizumab: Data from the International PNH Registry	17
Predicting primary treatment failure using interim FDG‐PET scanning in diffuse large B‐cell lymphoma	16
Bortezomib‐based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data	16
	15
Venous thromboembolism prophylaxis in hospitalized sickle cell disease and sickle cell trait patients	14
Relationship between hemoglobin, hemolysis, and transcranial Doppler velocities in children with sickle cell disease: Results from a long‐term natural history study in Italy in the era of multimodal t	14
Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1‐mRNA expression in patients with AML and MDS	14
Efficacy of COVID‐19 vaccination in adult patients with sickle cell disease during the Omicron wave in France	14
Are we ready for personalizedCAR‐Ttherapy?	13
Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes	13
Soluble MIC‐A, IPI, and response to treatment strongly predict survival in patients with germinal center diffuse large B cell lymphoma	13
A low‐dose rituximab regimen for first‐line treatment of acquired haemophilia A	13
BAY 81‐8973 Demonstrates Long‐Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study	13
Intracranial hemorrhage in newly diagnosed non‐promyelocytic acute myeloid leukemia patients admitted for intensive induction chemotherapy	12
Home‐Based Daratumumab in Patients With Multiple Myeloma	12
Health‐related quality of life in patients with β‐thalassemia: Data from the phase 3 BELIEVE trial of luspatercept	12
Transfusion requirements and complication rate in β‐thalassemia intermedia due to heterozygous β‐globin gene mutation and triplicated α‐globin genes	12
Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine	12
Antiemetic prophylaxis regimens in haematologic malignancies patients undergoing a hematopoietic stem cell transplantation. Which is the best standard of care? A systematic review	11
HyperCVAD versus pegaspargase‐containing regimens for Hispanic adults with newly diagnosed B‐cell acute lymphoblastic leukemia	11
Repeated immunosuppressive rabbit antithymocyte globulin therapy for adult patients with relapsed or refractory aplastic anemia	11
Issue Information	11
Platelet kinetics in patients with chronic immune thrombocytopaenia treated with thrombopoietin receptor agonists	11
Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies	11
Adherence and Quality of Life in Adult Patients With Haemophilia A, Haemophilia B and Von Willebrand Disease: A National Cross‐Sectional Survey	11
Outcomes of COVID‐19 hospitalizations in patients with sickle cell disease: A nationwide analysis	10
BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population	10
Issue Information	10
	10
Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysis	10
End of treatment FDG‐PET in primary mediastinal B‐cell lymphoma treated with R‐chemotherapy: Prognostic indicator and implications for consolidation radiotherapy	10
Sequencing and combination of currentsmall‐moleculeinhibitors for chronic lymphocytic leukemia: Where is the evidence?	9
Secondary Malignancies After Autologous Stem Cell Transplantations in Patients With Malignant Lymphoma and Multiple Myeloma	9
A post hoc analysis of PROTECT VIII Kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A	9
Issue Information	9
Clinicopathological Prognostic Model for Survival in Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis	9
Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX‐FP in the PROLONG‐9FP clinical trial program	9
Hematological and genetic profiles of persons with co‐inherited heterozygous β‐thalassemia and supernumerary α‐globin genes	9
Relationships between T‐lymphocytes and physical function in adults with chronic lymphocytic leukemia: Results from the HEALTH4CLL pilot study	9
Estrogen‐based hormonal therapy and the risk of thrombosis in COVID‐19 patients	9
Long‐term remission in a patient with relapsed Richter's transformation treated with CD19‐directed chimeric antigen‐receptor T‐cells after allogeneic stem cell transplantation	9
	8
Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem‐cell support for refractory/relapsed multiple myeloma	8
Autologous stem cell transplantation in multiple myeloma patients over 70 years: A GIMEMA Lazio Working Group experience in a retrospective case–control study	8
Three cases of late‐onset post CAR‐T therapy isolated CNS relapse in R/R large B‐cell lymphoma	8
Retracted: Bevacizumab synergises with the BCL 2 inhibitor venetoclax to effectively treat B‐cell non‐Hodgkin's lymphoma	8
The incidence, complications, and treatment of iron deficiency in pregnancy	8
Long‐term haematological response and maintained immunological function after laparoscopic subtotal splenectomy in patients with hereditary spherocytosis	8
Asciminib in Advanced‐Line Treatment of Chronic Myeloid Leukemia	8

Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition	8
Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)	8
Persistent decreased bone marrow CD3+CD56+ T lymphocytes are inversely associated with mature granulocytes in myelodysplastic syndromes	8
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow‐up subgroup analysis of the BOSTON trial	8
Use of midostaurin in mixed phenotype acute leukemia with FLT3 mutation: A case series	8
Risk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir‐exposed CMV‐free population receiving PTCy	7
Anti‐thymocyte Globulin and Post‐Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen‐A and ‐B mismatched donors	7
Global prevalence of anemia among women of reproductive age, 2000–2019	7
Clinical outcomes of patients referred for asymptomatic neutropenia: A focus on racial disparities in hematology	7
Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review	7
Phenotype of BTK‐lacking myeloid cells during prolonged COVID‐19 and upon convalescent plasma	7
	7
Comparison of outcomes between Hodgkin's lymphoma patients treated in and outside clinical trials: A study based on theEORTC‐Dutchlate effects cohort‐linked data	7
Survival and risk of vascular complications in myelofibrosis—A population‐based study from the Swedish MPN group	7
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study	7
Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study	7
ProGraME: A novel flow cytometry algorithm for the diagnosis of low‐risk myelodysplastic syndromes in patients with cytopenia	7
Hematopoietic cell transplantation for telomere biology diseases: A retrospective single‐center cohort study	7
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents	7
Development and validation of the sickle cell stress scale‐adult	7
	7
A precision‐based exercise program for patients with multiple myeloma	7
Fecal microbiota transfer for refractory intestinal graft‐versus‐host disease — Experience from two German tertiary centers	7
	7
	7
	7
Implementation of International Prognostic Index with flow cytometry immunophenotyping for better risk stratification of chronic lymphocytic leukemia	6
Insulin‐like growth factor‐1 and insulin‐like growth factor binding protein‐3: impact on early haematopoietic reconstitution following allogeneic haematopoietic stem cell transplantation	6
Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review	6
Fetal Hemoglobin Decrease During Voxelotor Treatment	6
Musculoskeletal Symptoms and Misdiagnoses in Children With Acute Myeloid Leukaemia: A Nationwide Cohort Study	6
Dose intensity and treatment duration of bortezomib in transplant‐ineligible newly diagnosed multiple myeloma	6
Trends and in‐hospital cardiac complications in patients with atrial fibrillation undergoing allogeneic stem cell transplant: A National Inpatient Sample analysis (2002–2019)	6
	6
Interferon gamma regulates a complex pro‐survival signal network in chronic lymphocytic leukemia	6
Screening for multidrug‐resistant organisms in high‐risk hospitalized patients with hematologic diseases	6
Relevance, Risks, and Benefits of Early‐Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023	6
Variability of treatment modalities and intensity in patients with severe haemophilia A on prophylaxis: Results from the Italian national registry	6
Issue Information	6
MCIR1: A patient‐derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance	6
Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: A single center analysis	6
JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms	6
Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study	6
Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning	6
The applicability of the central line‐associated bloodstream infection (CLABSI) criteria for the evaluation of bacteremia episodes in pediatric oncology patients	6
Risk‐based and individualised management of bleeding and thrombotic events in adults with primary immune thrombocytopenia (ITP)	6
Chimeric antigen receptor T cells for acute myeloid leukemia	6
Re‐evaluation of rituximab therapy for idiopathic Castleman disease: Retrospective study from single‐center experience	6
Outcomes in Kaposi's sarcoma‐associated herpesvirus ‐associated primary effusion lymphoma and multicentric Castleman's disease in patients with human immunodeficiency virus (	6
	6
Pattern of use and clinical outcomes with rIX‐FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real‐world study	6
Clinical Management of Persistent Hypereosinophilia	6
Long‐term outcome in patients with follicular lymphoma following high‐dose therapy and autologous stem cell transplantation	6
Lymph node core needle biopsy in lymphoproliferative disorders—Authors’ reply to Al‐Abbadi and colleagues	6
Exercise in newly diagnosed patients with multiple myeloma: A randomized controlled trial of effects on physical function, physical activity, lean body mass, bone mineral density, pain, and quality of	6
Bone marrow expression of CD68/CD163 macrophages, IL‐17 and FOXP3 cells in aplastic anemia and their relation to prognosis	6
15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy (anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment in B‐lymphoblastic le	6
Combinatorial treatment for unresectable unicentric Castleman disease	6
Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management	6
Venetoclax in the Treatment of Multiple Myeloma: A Retrospective Analysis of 79 Patients	5
Efficacy and safety of PD‐1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients	5
Haematology Outcomes Network in Europe (HONEUR)—A collaborative, interdisciplinary platform to harness the potential of real‐world data in hematology	5
A prospective study of posttransplant cyclophosphamide for unrelated donor peripheral blood stem cell transplant with special attention to graft content and the impact of a higher γδ T cell dose	5
A post hoc analysis of PROTECT VIII kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A	5
	5
Effectiveness of progressive moderate‐vigorous intensity elastic resistance training on quality of life and perceived functional abilities in people with hemophilia: Secondary analysis of a randomized	5
Validation of the GATMO score in predicting non‐relapse mortality following hematopoietic cell transplant in multiple myeloma patients	5
Appropriateness of inpatient intravenous iron therapy in a Swiss tertiary care hospital	5
The current challenges faced by people with hemophilia B	5
Efficacy of conventional‐dose cytarabine, idarubicin and thioguanine versus intermediate‐dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long‐term results of the p	5
Evaluation of soluble P‐selectin as a predictive biomarker in acute symptomatic pulmonary embolism: Insights from a prospective observational study	5
Venetoclax Combined With FLAG‐IDA in Refractory or Relapsed Acute Myeloid Leukemia	5
Recombinant factor IX Fc for the treatment of hemophilia B	5
Clinical characteristics of Australian treatment‐naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry	5
Treatment of Refractory Monoclonal Immunoglobulin Deposition Disease With BCMA Bispecific Antibody	5
Risk of infection according to the gamma globulin level in the 100 days following allogeneic stem cell transplantations	5
Real‐world utility of early measurable residual disease assessments by multi‐parametric flow cytometry in adult patients with B‐lymphoblastic leukemia receiving Hyper‐CVAD induction chemoth	5
Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T‐cell therapy	5
Issue Information	5
Featured Cover	5

	5
Effect of pre‐transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis	5
Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care	5
Busulfan and cyclophosphamide‐based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion‐dependent thalassem	5
The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of network meta‐analysis	5
Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies	5
Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real‐world retrospective study	5
The management, outcome, and postpartum disease course of 41 pregnancies in 20 women with polycythemia vera	5
ABO Blood Type and Short‐Term Mortality in Patients With Infection‐Associated Disseminated Intravascular Coagulation	5
Global reported impacts of COVID‐19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic	4
LP2, a stable lanthipeptide derived from cAng‐(1‐7), exerts myeloprotective action in mice	4
	4
Biological Findings and Clinical Outcomes in Patients Treated With R‐CHOP Plus High‐Dose Methotrexate as First‐Line Therapy in Large B‐Cell Lymphoma With Testis Involvement	4
Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant‐ineligible patients with myeloma who are treated with bortezomib‐based induction	4
Herpes zoster prophylaxis with low‐dose acyclovir in patients with malignant lymphoma and multiple myeloma treated with autologous stem cell transplantation	4
Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation	4
Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib—A retrospective analysis on consecutive patients fr	4
Resveratrol and tetrahydroisoquinoline effects on neutrophil sensitivity to NETosis formation in low‐risk essential thrombocythemia patients	4
Assessing the Burden of C5 Inhibitor Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria	4
Racial disparities in the incidence and survival outcomes in diffuse large B‐cell lymphoma in adolescents and young adults	4
Issue Information	4
Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups	4
Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma	4
Venetoclax induces deep and durable minimal residual disease‐negative remission in high‐risk TP53 disrupted B prolymphocytic leukaemia	4
Marked hyperferritinemia in critically ill cancer patients	4
Retrospective study on pomalidomide‐PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma	4
A New Strategy for Adult T‐Cell Leukemia Treatment Targeting Glycogen Synthase Kinase‐3β	4
Utilization of a surgical database to provide care and assess perioperative treatment and outcomes in patients with bleeding disorders	4
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation	4
Real‐World Evidence of Crizanlizumab Showing Reductions in Vaso‐Occlusive Crises and Opioid Usage in Sickle Cell Disease	4
Issue Information	4
Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries	4
Clonal haematopoiesis of indeterminate potential and impaired kidney function—A Danish general population study with 11 years follow‐up	4
Treatment horizon in multiple myeloma	4
Increased Non‐Relapse Mortality in Older People With Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine and Myeloablative Dose of Busulfan‐Based Regimen	4
Issue Information	4
Childhood autoimmune hemolytic anemia: A scoping review	4
The Mortality of Adults With Sickle Cell Disease at a Comprehensive Sickle Cell Center	4
Cytogenetic and molecular characteristics and outcomes of adult patients with early T‐cell precursor acute lymphoblastic leukemia	4
The safety of Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A systematic review	4
Comparison of telomere length in patients with bone marrow failure syndromes and healthy controls	4
Further Reflections on 6‐MP Adherence and Habit Strength: The Impact of Dose Adjustment Complexity and Caregiver Burden	4
Apheresis collection of mononuclear cells for chimeric‐antigen receptor therapies	4
Improved Outcomes of Myeloma Cast Nephropathy in Newly Diagnosed Multiple Myeloma With Modern Anti‐Myeloma Therapies	4
Hyper‐CVAD and Modified CALGB‐10403 Regimens in Adult Patients With Philadelphia‐Negative Acute Lymphoblastic Leukemia: A Comparative Study	4
Differences in patient‐reported outcomes (PROs) by disease severity in light chain (AL) amyloidosis	4
Immunophenotyping for the Assessment of Asymptomatic Lymphocytosis: A Retrospective Analysis and National Survey	4
Chronic myeloid leukemia (CML) in children and adolescents—Clinicopathological findings	4
Tandem bispecific CD123/CLL‐1 CAR‐T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia	4
VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation	4
Changes in body mass index during treatment of childhood acute lymphoblastic leukemia with the Nordic ALL2008 protocol	4
The impact of hematology electronic consultations on the management of iron deficiency	4
Health‐related quality of life in patients with steroid‐refractory acute graft‐versus‐host disease	4
Treatment of Critical Bleeds in Patients With Immune Thrombocytopenia: A Systematic Review	4
	4
The role of oral iron in the treatment of adults with iron deficiency	4
Unveiling the Genetic and Clinical Differences of Acute Myeloid Leukemia (AML) in Obese Patients	4
CLLAF SCORE—A New Risk Score for Predicting Atrial Fibrillation in Treatment‐Naive CLL Patients Initiating First‐ and Second‐Generation BTK Inhibitor Therapy	4